Nadroparin in the Prevention of Deep Vein Thrombosis in Acute Decompensated COPD
| Autor: | Patrick Herbecq, Jean-Michel Couland, Bernard Bedock, Jean-François Poussel, Laurent Holzapfel, François Fraisse, Louis Roux, Gérald Simonneau, Reginald Pordes, Marc Feissel |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty medicine.drug_class business.industry Deep vein Anticoagulant Low molecular weight heparin Critical Care and Intensive Care Medicine Nadroparin calcium Placebo Surgery medicine.anatomical_structure Anesthesia Chemoprophylaxis Nadroparin medicine business Adverse effect medicine.drug |
| Zdroj: | American Journal of Respiratory and Critical Care Medicine. 161:1109-1114 |
| ISSN: | 1535-4970 1073-449X |
| Popis: | Low molecular weight heparins are as effective as unfractionated heparin in deep-vein thrombosis (DVT) prophylaxis for major surgery. However, there is no evidence nor consensus for prophylaxis in medical patients. We compared the efficacy and safety of nadroparin calcium (nadroparin) with placebo in medical patients at high risk of DVT. A total of 223 patients mechanically ventilated for acute, decompensated chronic obstructive pulmonary disease, were randomized to treatment with subcutaneous nadroparin adjusted for body weight (0.4 ml, i.e., 3,800 AXa IU, or 0.6 ml, i.e., 5,700 AXa IU) or placebo. The average duration of treatment was 11 d. The incidence of DVT in patients receiving nadroparin was significantly lower than that in patients receiving placebo (15.5 versus 28.2%; p = 0.045). Although the incidence of adverse events was high in both groups, there were no significant differences between nadroparin and placebo for total adverse events (46.3 versus 39.8%; p = 0.33), serious adverse events (25.0... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|